Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 2401–2450 of 75328
The Board of Directors appointed James Woodend as the Company’s new Chief Executive Officer, effective immediately.
On May 8, Joe Cleghorn stepped down from his role as Chief Executive Officer of AMMJ (the "Company").
In addition, Mr. Woodend was appointed Chairman of the Board of Directors.
On May 6, the Board of Directors of AMMJ (the “Company”) appointed Griffin Brahms to serve as a member of the Company’s Board of Directors, effective immediately.
at the Effective Time, each of John Fowler, Franklin Berger, Graham Cooper, Elizabeth Garner, M.D., Michael Kauffman, M.D., Ph.D., Micki Klearman, M.D. and Courtney Wallace resigned from the board of directors of the Company.
at the Effective Time, each of John Fowler, Franklin Berger, Graham Cooper, Elizabeth Garner, M.D., Michael Kauffman, M.D., Ph.D., Micki Klearman, M.D. and Courtney Wallace resigned from the board of directors of the Company.
The executive officers of Merger Sub immediately prior to the Effective Time were Kevin Tang, Chief Executive Officer, Ryan Cole, Chief Operating Officer, Michael Hearne, Chief Financial Officer, and Stephen Robertson, Chief Legal Officer, Corporate Secretary and Chief Compliance Officer.
at the Effective Time, each of John Fowler, Franklin Berger, Graham Cooper, Elizabeth Garner, M.D., Michael Kauffman, M.D., Ph.D., Micki Klearman, M.D. and Courtney Wallace resigned from the board of directors of the Company.
at the Effective Time, each of John Fowler, Franklin Berger, Graham Cooper, Elizabeth Garner, M.D., Michael Kauffman, M.D., Ph.D., Micki Klearman, M.D. and Courtney Wallace resigned from the board of directors of the Company.
at the Effective Time, each of John Fowler, Franklin Berger, Graham Cooper, Elizabeth Garner, M.D., Michael Kauffman, M.D., Ph.D., Micki Klearman, M.D. and Courtney Wallace resigned from the board of directors of the Company.
The executive officers of Merger Sub immediately prior to the Effective Time were Kevin Tang, Chief Executive Officer, Ryan Cole, Chief Operating Officer, Michael Hearne, Chief Financial Officer, and Stephen Robertson, Chief Legal Officer, Corporate Secretary and Chief Compliance Officer.
The executive officers of Merger Sub immediately prior to the Effective Time were Kevin Tang, Chief Executive Officer, Ryan Cole, Chief Operating Officer, Michael Hearne, Chief Financial Officer, and Stephen Robertson, Chief Legal Officer, Corporate Secretary and Chief Compliance Officer.
Christopher J. Kirk, Ph.D., Marc L. Belsky and Mark Schiller entered into separation agreements with the Company. Each officer’s employment with the Company will terminate at the Effective Time.
Christopher J. Kirk, Ph.D., Marc L. Belsky and Mark Schiller entered into separation agreements with the Company. Each officer’s employment with the Company will terminate at the Effective Time.
Christopher J. Kirk, Ph.D., Marc L. Belsky and Mark Schiller entered into separation agreements with the Company. Each officer’s employment with the Company will terminate at the Effective Time.
The executive officers of Merger Sub immediately prior to the Effective Time were Kevin Tang, Chief Executive Officer, Ryan Cole, Chief Operating Officer, Michael Hearne, Chief Financial Officer, and Stephen Robertson, Chief Legal Officer, Corporate Secretary and Chief Compliance Officer.
at the Effective Time, each of John Fowler, Franklin Berger, Graham Cooper, Elizabeth Garner, M.D., Michael Kauffman, M.D., Ph.D., Micki Klearman, M.D. and Courtney Wallace resigned from the board of directors of the Company.
the sole director and officers of Merger Sub immediately prior to the Effective Time became the sole director and officers of the Surviving Corporation. The sole director of Merger Sub immediately prior to the Effective Time was Kevin Tang.
at the Effective Time, each of John Fowler, Franklin Berger, Graham Cooper, Elizabeth Garner, M.D., Michael Kauffman, M.D., Ph.D., Micki Klearman, M.D. and Courtney Wallace resigned from the board of directors of the Company.
each of Amanda M. Clark, Susan W. Muigai and Sabrina L. Simmons resigned from the Board and any and all committees thereof.
Sohaib Abbasi, Marylou Maco and Lydia Paterson, each of whom were directors of Udemy as of the date of the Merger Agreement, were appointed to the Board effective immediately following the Closing
Sohaib Abbasi, Marylou Maco and Lydia Paterson, each of whom were directors of Udemy as of the date of the Merger Agreement, were appointed to the Board effective immediately following the Closing
Sohaib Abbasi, Marylou Maco and Lydia Paterson, each of whom were directors of Udemy as of the date of the Merger Agreement, were appointed to the Board effective immediately following the Closing
each of Amanda M. Clark, Susan W. Muigai and Sabrina L. Simmons resigned from the Board and any and all committees thereof.
each of Amanda M. Clark, Susan W. Muigai and Sabrina L. Simmons resigned from the Board and any and all committees thereof.
At the Effective Time, Gregory M. Hart, Michael Foley, Alan B. Cardenas and Marcelo C. Modica became members of the board of directors of the Surviving Corporation.
At the Effective Time, Gregory M. Hart, Michael Foley, Alan B. Cardenas and Marcelo C. Modica became members of the board of directors of the Surviving Corporation.
At the Effective Time, Gregory M. Hart, Michael Foley, Alan B. Cardenas and Marcelo C. Modica became members of the board of directors of the Surviving Corporation.
At the Effective Time, Gregory M. Hart, Michael Foley, Alan B. Cardenas and Marcelo C. Modica became members of the board of directors of the Surviving Corporation.
Eric D. Brenner has been elected by the Company’s Board of Directors (the “Board”) as the Company’s Chief Financial Officer and Treasurer, in which position he will serve as the Company’s principal financial officer, effective May 26, 2026.
Bradley A. Pearce, interim Chief Financial Officer and Treasurer and Chief Accounting Officer, will return to his previous role as the Company’s Chief Accounting Officer, effective May 26, 2026.
On May 8, 2026, Mr. Jonathan D. Lanoy was appointed to serve as the Company’s Interim Principal Financial Officer.
On May 8, 2026, L. Shane Jones notified Nature’s Sunshine Products, Inc. (the “Company”) that he is resigning as the Company’s Chief Financial Officer effective June 5, 2026.
Our independent lead director, William B. Campbell, who has been a director of F.N.B. Corporation since 1975, did not stand for re-election and retired from our Board of Directors effective May 6, 2026.
On May 6, 2026, Deidre E. Cusack and Anne De Greef-Safft notified Brady Corporation (the "Company") of their respective resignations from the Company’s Board of Directors effective May 8, 2026.
On May 6, 2026, Deidre E. Cusack and Anne De Greef-Safft notified Brady Corporation (the "Company") of their respective resignations from the Company’s Board of Directors effective May 8, 2026.
Also on May 6, 2026, Ms. Nancy Reardon notified the Board of her decision not to stand for re-election to the Board at the Company’s 2026 Annual General Meeting of Shareholders to be held on June 26, 2026
On May 6, 2026, the Board of Directors (the “Board”) of Signet Jewelers Limited (“Signet” or the “Company”) appointed Mr. Jeffrey Gennette to the Board, effective immediately.
Nick L. Stanage was appointed to the Board of Directors of AMETEK, Inc., or the "Company" effective May 7, 2026 to serve as a Class III Director until the 2027 Annual Meeting.
On May 7, 2026, the Board of Directors, or the Board, of NVIDIA Corporation appointed Suzanne Nora Johnson as a member of the Board and as a member of the Audit Committee of the Board and the number of directors constituting the full Board was increased from ten to eleven, in each case effective July 13, 2026.
On April 30, 2026, Deborah Casper-Stone resigned from her position as Chief Financial Officer of Cyber Enviro-Tech, Inc. (the “Company”), effective the same date.
On April 30, 2026, the Company reappointed Dan Leboffe as its Chief Financial Officer, effective immediately.
Alex Corbacho, Robert DeBorde, Randy Papadellis, Mark Partin, Kevin Schwartz, and Kathy Vrabeck were appointed to the Company’s board of directors.
Alex Corbacho, Robert DeBorde, Randy Papadellis, Mark Partin, Kevin Schwartz, and Kathy Vrabeck were appointed to the Company’s board of directors.
Alex Corbacho, Robert DeBorde, Randy Papadellis, Mark Partin, Kevin Schwartz, and Kathy Vrabeck were appointed to the Company’s board of directors.
Alex Corbacho, Robert DeBorde, Randy Papadellis, Mark Partin, Kevin Schwartz, and Kathy Vrabeck were appointed to the Company’s board of directors.
Alex Corbacho, Robert DeBorde, Randy Papadellis, Mark Partin, Kevin Schwartz, and Kathy Vrabeck were appointed to the Company’s board of directors.
Alex Corbacho, Robert DeBorde, Randy Papadellis, Mark Partin, Kevin Schwartz, and Kathy Vrabeck were appointed to the Company’s board of directors.
On May 7, 2026, Evert Schimmelpennink, a member of the Board, notified the Company of his decision to resign from the Board, including from his position as a member of the Compensation Committee of the Board, effective immediately.
On May 7, 2026, the Board of Directors (the “Board”) of iBio, Inc. (the “Company”), following the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Dr. Elizabeth Stoner, M.D., M.S., to serve as a Class II director of the Company, effective May 7, 2026
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.